Normal tissue considerations and dose-volume constraints in the moderately hypofractionated treatment of non-small cell lung cancer.

[1]  J. Maguire,et al.  134 Long term local tumour control in inoperable NSCLC treated with accelerated hypofractionated radiotherapy and concurrent cisplatinum and vinorelbine , 2016 .

[2]  Joe Y. Chang,et al.  Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. , 2015, Clinical lung cancer.

[3]  N. O'Rourke,et al.  SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status. , 2014, European journal of cancer.

[4]  H. Groen,et al.  Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer , 2014, Radiation Oncology.

[5]  C. Rowbottom,et al.  An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer? , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  J. Greenland,et al.  Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. , 2014, Journal of the National Cancer Institute.

[7]  L. Quint,et al.  Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer. , 2014, International journal of radiation oncology, biology, physics.

[8]  D. Landau,et al.  Optimizing collimator margins for isotoxically dose-escalated conformal radiation therapy of non-small cell lung cancer. , 2014, International journal of radiation oncology, biology, physics.

[9]  A. Nahum,et al.  148 Dose escalation in the I-START trial – ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer , 2014 .

[10]  J. Sonke,et al.  Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[11]  Pranshu Mohindra,et al.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. C. Pressello,et al.  Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer , 2013, Front. Oncol..

[13]  Jeffrey D Bradley,et al.  Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[14]  R. Talamini,et al.  Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen , 2013, BMC Cancer.

[15]  S. Harden,et al.  Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  A. Bäck,et al.  Influence of different dose calculation algorithms on the estimate of NTCP for lung complications , 2013, Journal of applied clinical medical physics.

[17]  Qiang Lin,et al.  Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial , 2013, Radiation oncology.

[18]  J. Sonke,et al.  Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  H. Pyo,et al.  Hypofractionated Three-Dimensional Conformal Radiation Therapy Alone for Centrally Located cT1-3N0 Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[21]  V. De Sanctis,et al.  Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. , 2013, International journal of radiation oncology, biology, physics.

[22]  Jeffrey D Bradley,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[23]  Xavier Franceries,et al.  Plate-based transfection and culturing technique for genetic manipulation of Plasmodium falciparum , 2012, Malaria Journal.

[24]  D. Goldstein,et al.  Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.

[25]  A J Hope,et al.  Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer. , 2012, Current oncology.

[26]  N Hodapp,et al.  [The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. , 2012, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[27]  P. Baas,et al.  152 Clinical prediction for acute toxicity in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiation , 2012 .

[28]  I. Yeo,et al.  Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy , 2011, Journal of applied clinical medical physics.

[29]  Søren M Bentzen,et al.  Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques , 2010, Acta oncologica.

[30]  K. Tournel,et al.  Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. , 2010, International journal of radiation oncology, biology, physics.

[31]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[32]  Joseph O. Deasy,et al.  Radiation dose-volume effects in the esophagus. , 2010, International journal of radiation oncology, biology, physics.

[33]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[34]  V. Tombolini,et al.  Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer. , 2010, Lung cancer.

[35]  T. Kimura,et al.  Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer , 2009, International Journal of Clinical Oncology.

[36]  Heung Tae Kim,et al.  A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study. , 2009, International journal of radiation oncology, biology, physics.

[37]  K. Bujko,et al.  Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  B. Yaremko,et al.  Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  Branislav Jeremic,et al.  Isodose-based methodology for minimizing the morbidity and mortality of thoracic hypofractionated radiotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  M. Leitch,et al.  Oesophageal toxicity and hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[41]  D. Hayes,et al.  Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  H Jaradat,et al.  Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study , 2008, Technology in cancer research & treatment.

[43]  Radhe Mohan,et al.  Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[44]  G. Giaccone,et al.  Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). , 2007, European journal of cancer.

[45]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[46]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[47]  Laurence Court,et al.  Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. , 2006, International journal of radiation oncology, biology, physics.

[48]  W. Curran,et al.  Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.

[49]  R. T. Ten Haken,et al.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.

[50]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[51]  M. Socinski,et al.  Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? , 2005, International journal of radiation oncology, biology, physics.

[52]  O. Holmberg,et al.  Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  Andrew Morgan,et al.  Dosimetric verification of a commercial collapsed cone algorithm in simulated clinical situations. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  A Nisbet,et al.  The clinical implications of the collapsed cone planning algorithm. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[55]  Joos V Lebesque,et al.  Incorporating an improved dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of dose in normal lung tissue. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  W. Curran,et al.  Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. , 2001, Chest.

[57]  J. Bernier,et al.  Quantitative clinical radiobiology of early and late lung reactions. , 2000, International journal of radiation biology.

[58]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[59]  R K Ten Haken,et al.  Fraction size and dose parameters related to the incidence of pericardial effusions. , 1998, International journal of radiation oncology, biology, physics.

[60]  D. Girling,et al.  Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[61]  P. Rubin,et al.  Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group , 1987, Cancer.